Alzheimer disease is intimately linked to an excess amount of amyloid-β (Aβ) in the brain. Thus, therapeutic inhibition of Aβ production is an attractive clinical approach to treat this disease. Here we provide the first direct experimental evidence that the treatment of Tg2576 transgenic mice with an inhibitor of β-secretase, GRL-8234, rescues the age-related cognitive decline. We demonstrated that the injected GRL-8234 effectively enters the brain and rapidly decreases soluble Aβ in the brain of Tg2576 mice. The rescue of cognition, which was observed only after long-term inhibitor treatment ranging from 5 to 7.5 mo, was associated with a decrease of brain amyloid-β plaque load. We also found no accumulation of amyloid-β precursor protein after several months of inhibitor treatment. These observations substantiate the idea that Aβ accumulation plays a major role in the cognitive decline of Tg2576 mice and support the concept of Aβ reduction therapy as a treatment of AD.

Original languageEnglish
Pages (from-to)775-784
Number of pages10
JournalFASEB Journal
Issue number2
StatePublished - Feb 2011


  • Alzheimer's disease
  • Memapsin 2
  • Tg2576


Dive into the research topics of 'β-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice'. Together they form a unique fingerprint.

Cite this